Briacell Therapeutics Corp BCTX

$3.40 -0.37 (-9.69%)

Valuation

Market cap
32,755,000
Revenue TTM
$0
Net income TTM
$-26,310,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
136,700
Avg volume
316,000
Day's range
$3.39 – $3.91
Shares out
8,700,000
Stochastic %K
1%
Beta
1.21
Analysts
Strong Buy
Price target
$40.00

Price

Company profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator...

Show more

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 921 1810
Website
https://briacell.com
Address
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

Latest news

Stocktwits

Biotechlineup Oct 17, 2:44 PM
$BCTX Just a casual remark. Doesn’t this just amaze everyone?? "We're getting extremely interesting results already with our first patient who came in, had a lung metastasis, had failed several prior therapy attempts and with four cell inoculations every two weeks, the lung metastasis completely cleared..."
0 replies
Biotechlineup Oct 17, 2:10 PM
$BCTX Just another speculation, in the worst case scenario where they miss the .7 HR in the combined arm . Think about this the TNBC patients subgroup in phase 2 had a .54 HR ! With minimal side effects. So drastically almost doubles life expectancy with a high quality of life. Another speculation even in that case the FDA carves out an approval for the sub group.
0 replies
Biotechlineup Oct 17, 1:57 PM
$BCTX This is why biotech investing is a lot of speculation. The key word was “Hockey Stick” few weeks ago they implied enrollment had accelerated rapidly from the May/26 180 patients because it had gone hockey stick. When asked about an update , management said we will wait until full enrollment. Boom ! They confirmed it’s done. Now they were very confident on a year end read out. How can that be?? Many of us have run multi variable Monte Carlo’s . Only way is if the TNBC group is overly represented . Management is not completely blinded, they can infer from other parameters the mix. Thats my speculation.
0 replies
JediGreen Oct 17, 6:17 AM
$BCTX https://www.investors.com/news/technology/biotech-stocks-2026-mergers-acquisitions-2027-forecast/
0 replies
JediGreen Oct 17, 4:19 AM
$BCTX This might be a really good sign. I’d consider this shaking the tree 🌳. My opinion someone is trying to get people out to cover or load up or could even be market makers.
0 replies
Biotechlineup Oct 17, 3:29 AM
$BCTX So according to management using present tense language with 177 already enrolled in each arm , the 354 total did truly Hockey stick as they previously stated. I think that went over the analysts head. This is now being driven by the control arm. Very likely management has a good feel for the expectations on the previous year end expectations. Since they said cash run through 2nd qtr and expenses drop rapidly in the observable stage of a trial , all we have to do is wait.
1 replies
BHWinehouse Oct 16, 9:46 PM
$LPCN $BCTX
0 replies
CoffeeRocks Oct 16, 9:32 PM
$LPCN Waiting for a BiG drop also $BCTX Both sub dollar 🔜
0 replies